We appear to be poised on a new era for treating a variety of cardiovascular conditions with renal artery denervation, a percutaneous technique that disrupts the renal sympathetic nervous system using ablation. In this issue of Cardiovascular Business, we talk with interventional cardiologists and electrophysiologists about its potential as a treatment for drug-resistant hypertension, atrial fibrillation and heart failure. While not approved in the U.S., the technique already has been approved for refractory hypertension in parts of Europe and Australia.